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ABSTRACT
Background: Long-term outcomes after lung transplantation are often limited by the development of
obliterative bronchiolitis (OB), which is clinically defined using spirometry as bronchiolitis obliterans
syndrome (BOS). Lung clearance index (LCI), derived from multiple breath washout (MBW) testing, is a
global measure of ventilation heterogeneity that has previously been shown to be a more sensitive measure
of obstructive small airway diseases than spirometry. We aimed to assess the feasibility of LCI in adult
lung transplant patients and to compare LCI to BOS grade.
Methods: 51 stable adult double-lung transplant recipients performed sulfur hexafluoride MBW in
triplicate on a single occasion, using a closed-circuit Innocor device. BOS grades were derived from serial
spirometry according to International Society for Heart and Lung Transplantation criteria and, where
available, high-resolution computed tomography (HRCT) evidence of OB was recorded.
Results: LCI was successfully performed in 98% of patients. The within-visit coefficient of variation for
repeat LCI measurements was 3.1%. Mean LCI increased significantly with BOS grades: no BOS (n=15),
LCI 7.6; BOS-0p (n=16), LCI 8.3; BOS-1 (n=11), LCI 9.3; BOS-2–3 (n=9), LCI 13.2 (p<0.001). 27 patients
had HRCT within 12 months. LCI in those with HRCT evidence of OB was higher than those without OB
(11.1 versus 8.2, p=0.006). 47% patients displayed abnormal LCI (>7) despite a normal forced expiratory
volume in 1 s (FEV1) (>80% of baseline).
Conclusions: LCI measurement in lung transplant recipients is feasible and reproducible. LCI increased
with increasing BOS grade. A significant proportion of this cohort had abnormal LCI with preserved
FEV1, suggesting early subclinical small airway dysfunction, and supporting a role for MBW in the early
identification of BOS.
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Chronic lung allograft dysfunction (CLAD) curtails medium- and long-term outcomes after lung
transplantation [1]. Obliterative bronchiolitis (OB) is the predominant phenotype of CLAD and is typified
by lymphocytic infiltration of the bronchioles, peribronchiolar fibrosis and constriction of the bronchial
lumen [2]. This pathology is not uniform throughout the graft and is seldom captured by surveillance
transbronchial biopsies, making histological confirmation of OB challenging. The term bronchiolitis
obliterans syndrome (BOS) has therefore been adopted as a clinical surrogate for OB. This reflects
progressive airflow limitation diagnosed by serial spirometry testing during routine clinical follow-up. The
International Society for Heart and Lung Transplantation (ISHLT) defines BOS as a ⩾20% drop in forced
expiratory volume in the first second (FEV1) from a stable post-transplant baseline, persistent over
⩾3 weeks and not explained by other reversible pathologies [1]. Air trapping on expiratory high-resolution
computed tomography (HRCT) of the chest further supports the diagnosis, whilst excluding alternative
causes of FEV1 decline. Spirometry, however, is recognised to be poor at detecting early small airway
changes [3]. Considerable peripheral lung damage can occur in airways <2 mm in diameter before this is
sufficient to impact on air flows at the mouth [4, 5].
Multiple breath washout (MBW) testing is an alternative assessment of lung physiology that measures
efficiency of gas mixing in the lungs by following the washout of an inert tracer gas during normal relaxed
breathing [3]. In the presence of airway disease, there is uneven filling and emptying of different lung
regions. This reduces efficiency of tracer gas washout and increases the lung clearance index (LCI), a
global measure of ventilation heterogeneity [6]. LCI is very sensitive to early airways disease [7] and has
been widely adopted by the cystic fibrosis (CF) community in clinical studies and trials [8], as well as
being used in asthma and COPD [9, 10]. In a past study of lung transplant patients, ventilation
heterogeneity appeared to be an early feature of BOS [11]. Recent assessments of MBW have all supported
this, despite being predominantly small cross-sectional studies in differing populations, and using different
tracer gases and indices of ventilation heterogeneity [12–14].
MBW testing is not without its challenges, however, including in particular the time taken to complete
testing, which can be prolonged even in those with relatively mild disease [10]. Clinical scalability requires
a test that is both sensitive to OB and clinically practical. Recent advances in MBW methodology offers
the possibility of shorter test times [15] but has not yet been widely reported in practice [16]. We
hypothesised that MBW would be feasible and reproducible in adult lung transplant recipients, and that
LCI would be able to differentiate between patients with different BOS grades. The aims of this study were
therefore:
• to determine feasibility of LCI testing using a closed-circuit wash-in method in an outpatient clinical
setting in adult lung transplant patients, defined as measurement success rates, testing time and
reproducibility of repeat measurements;
• to compare LCI to spirometry; and
• to compare LCI to ISHLT BOS grades (defined spirometrically) and to HRCT evidence of OB.
Patients and methods
Clinical setting
This was a cross-sectional study of clinically stable, adult, double-lung (DLTx) or heart–lung transplant
(HLTx) recipients, ⩾18 years of age, attending routine review at the Manchester Cardiothoracic Unit
(Manchester, UK), running recruitment and data collection between May 2017 and 2018. Patients were
recruited sequentially from the clinic depending on the availability of staff. The study size was
opportunistic, and patients were excluded if clinically unstable, undergoing active treatment for acute
pulmonary and/or extrapulmonary complications, colonised with communicable infections or unable to
perform reproducible spirometry. Patients gave informed consent and study procedures were carried out in
accordance with good clinical practice guidelines and the Declaration of Helsinki. This study was approved
by the local Research Ethics Committee (ref. 13/NW/0248).
Lung function measurements
More detailed descriptions of each of the assessments can be found in the supplementary material. Briefly,
MBW was performed using sulfur hexafluoride (SF6) as the inert tracer gas, measured using an Innocor
photoacoustic gas analyser (Innovision, Odense, Denmark) and a closed-circuit wash-in as previously
described [15]. At least three wash-out measurements were conducted and reported outcomes are the
mean of measures from at least two successful repetitions. LCI was defined as the number of lung
turnovers needed to wash SF6 to <1/40th of the starting concentration. The upper limit of normal for LCI
was 7 (supplementary material) [17].
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Test time was derived from the wash-out file length (in seconds, and presented in minutes). This includes
device warm-up time (60 s per test) and any intervals between tests. It does not include time taken to
explain the test or clean the apparatus between patients.
Routine spirometry was performed after MBW using a VMAX 22 system (SensorMedics, Yorba Linda,
CA, USA) in accordance with American Thoracic Society/European Respiratory Society guidelines [18].
Results are expressed as percentage of baseline, i.e. best value achieved post-transplant [1]. All tests were
carried out by a single physiologist (M. Driskel)
BOS status
The BOS stage for each patient was calculated according to ISHLT spirometric thresholds. No BOS was
defined as FEV1 >90% of baseline and forced expiratory flow at 25–75% of forced vital capacity
(FEF25–75%) >75% of baseline, BOS-0p (pre-BOS) as FEV1 81–90% of baseline and/or FEF25–75% ⩽75% of
baseline, BOS-1 as FEV1 66–80%, BOS-2 as FEV1 51–65%, and BOS 3 as FEV1 ⩽50% [1].
For HRCT diagnosis of OB, expiratory HRCT examinations within 12 months of the study visit were
included and expiratory air trapping explicitly attributed to OB by the reporting radiologist was noted.
Statistical analysis
All data were analysed using Prism version 6.04 (GraphPad Software Inc., La Jolla, CA, USA). The
D’Agostino and Pearson normality test was used to determine data distribution. The Kruskal–Wallis test
was used to compare LCI across BOS stages. Patients with BOS grades 2 and 3 (comprising seven and two
patients respectively) were grouped for analysis. For this exploratory dataset, the primary comparisons of
clinical interest were differences in LCI between patients with no BOS and those with BOS-0p and BOS-1,
as well as between those with BOS-0p and BOS-1. Therefore, to retain the power of the study to detect
these clinically relevant differences we have not made adjustments for multiple comparisons and present
all paired data with unadjusted p-values, with significance set at p<0.05. For post hoc analysis, group
means were compared with unpaired Student’s t-test for normally distributed data and presented as




Table 1 summarises the clinical characteristics and demographics of the study cohort, comprising 49 DLTx
and two HLTx recipients. COPD was the main indication for lung transplantation (n=24), with CF,
pulmonary hypertension and interstitial lung disease accounting for 15, seven and five, respectively.
Median (IQR) age was 54 (43–63) years, with a median time since transplantation of 4 (0.9–5.9) years.
All patients received induction immunosuppression with antithymocyte globulin, and were maintained on
a combination of calcineurin inhibitors, cell cycle inhibitors and prednisolone. None was receiving mTOR
inhibitors during the study.
Practicality of MBW in lung transplant
55 patients attempted MBW testing, which was completed in 54 (98%) (supplementary material). One
subject was excluded from analysis due to inability to complete the test reliably; this patient was also
unable to perform technically acceptable spirometry results. Three patients’ datasets were also excluded
due to a technical fault in the flowmeter, which was subsequently rectified. The final study cohort was
therefore 51 patients.
Median (IQR) testing duration was 24 (15–39) min. The median (IQR) coefficient of variation for LCI
and functional residual capacity was 3.1 (2.1–5.2) and 3.4 (2.3–4.9) respectively.
Comparison of LCI with spirometry
43 (84%) patients had an elevated LCI. Figure 1 shows LCI plotted against FEV1 and FEF25–75% (both
expressed as % of baseline). 24 (47%) out of 51 patients had an abnormal LCI but a preserved FEV1
(>80%), whilst 10 (20%) patients had an abnormal LCI with both normal FEV1 and FEF25–75%.
LCI across ISHLT BOS staging
LCI measurements differed significantly by BOS stage (p<0.0001, Kruskal-Wallis test) (figure 2 and table 1).
In those with BOS-0p (pre-BOS), 88% had an abnormal LCI, with a mean±SD of 8.3±1.0 compared with
7.6±0.84 in those without BOS (p=0.0300). A significant difference was also observed between those
without BOS and BOS-1 (p<0.0001), as well as those with BOS-0p and BOS-1 (p=0.027, all analysed with
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unpaired t-test). BOS-2–3 was significantly higher than all other stages in pairwise comparisons
(Mann–Whitney test).
LCI versus HRCT
27 patients had HRCT results available within 12 months of MBW testing. LCI was significantly higher in
those with HRCT evidence of BOS (n=17) compared to those with no BOS on HRCT (n=10): median
(IQR) LCI 10.1 (9.1–12.9) versus 8.2 (7.1–9.3) (p=0.005, Mann–Whitney) (figure 3). In the 24 patients
who did not have recent HRCT, median (IQR) LCI was 8.1 (7.2–8.8).
Cardiogenic oscillations
In 27 (53%) patients, potentially significant cardiogenic oscillations were observed during wash-out. These
were graded as mild, moderate or severe based on potential impact on wash-out analysis (supplementary
material). In eight patients, these oscillations were severe enough to affect phase 3 slope analysis, as an
accurate phase 3 slope could not be identified throughout the traces. In seven washouts, this also meant a
clear end-point for wash-out could not be unequivocally determined due to superimposed oscillations.
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FIGURE 1 Forced expiratory volume in the first second (FEV1) and forced expiratory flow at 25–75% of forced
vital capacity (FEF25–75%) values as % best from baseline, against lung clearance index (LCI).
TABLE 1 Summary of demographics and results across International Society for Heart and Lung Transplantation bronchiolitis
obliterans syndrome (BOS) grades
Overall No BOS BOS-0p BOS-1 BOS-2–3 p-value
Subjects 51 15 16 11 9
Age years 51.5±13.7 47.4±16.8 52.6±10.9 52.2±13.9 55.6±12.5 0.690§
Time since transplant years 4.0 (0.9–5.9) 1.0 (0.6–8.8) 4.1 (2.4–4.8) 3.6 (0.9–6.3) 5.0 (3.9–6.1) 0.735ƒ
FEV1 % predicted 87 (68–95) 95 (94–97)*
,#,¶ 90±4.7*,#,¶ 74±5.6*,¶,+ 56±8.2*,#,+ <0.0001ƒ
LCI 8.8 (7.4–9.9) 7.6±0.84*,#,¶ 8.3±1.0*,#,¶ 9.3±1.0*,¶,+ 12.5 (10.8–14.1)*,#,+ <0.0001ƒ
Scond 0.04 (0.02–0.07) 0.02±0.017*
,#,¶ 0.04±0.03*,¶ 0.06±0.04+ 0.09±0.04+ <0.0001§
Sacin 0.24±0.13 0.19±0.08
¶ 0.19±0.11¶ 0.23±0.06¶ 0.40±0.12*,#,+ <0.0001§
Data are presented as mean±SD or median (interquartile range), unless otherwise stated. For post hoc comparisons, unpaired t-tests were
used where both cohorts were normally distributed (data expressed as mean±SD) or Mann–Whitney test for all others. FEV1: forced expiratory
volume in the first second; LCI: lung clearance index; Scond: ventilation heterogeneity of the conductive lung zone; Sacin: ventilation
heterogeneity of the acinar lung zone. *: p<0.05 versus BOS-0p, post hoc pairwise comparison; #: p<0.05 versus BOS-1, post hoc pairwise
comparison; ¶: p<0.05 versus BOS-2–3, post hoc pairwise comparison; +: p<0.05 versus no BOS, post hoc pairwise comparison; §: ANOVA;
ƒ: Kruskal–Wallis test.
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Phase 3 slope indices
Phase 3 slope analysis was successfully performed in 43 (84%) patients. Sacin was seen to increase along
with BOS grade and measures differed significantly between the four groups (p<0.0001, one-way ANOVA)
(table 1 and figure 4). No significant difference was observed in pairwise comparisons between the milder
stages (no BOS to BOS-1, t-test). Ventilation heterogeneity of the conductive lung zone (Scond) also
increased with BOS severity (p<0.0001, one-way ANOVA). Amongst the milder stages, significant
differences were seen between those with no BOS and BOS-0p (p=0.030), and no BOS and BOS-1
(p=0.002, both t-test).
Discussion
This is the first study to report several MBW indices in a sizeable cohort of adult lung transplant
recipients and to stratify results by BOS grade rather than simply the presence or absence of BOS. We have
shown that LCI and Scond increase with increasing BOS grade and separately, that LCI is higher in those
with HRCT evidence of OB. Importantly, we have also shown that LCI is feasible in an outpatient setting
using a novel rapid wash-in method, and that this allows measurements to be completed in <30 mins with
high success rates and within-visit repeatability. Measurement times and repeatability are as good as or
FIGURE 2 Lung clearance index
(LCI) against International Society
for Heart and Lung Transplantation
(ISHLT) bronchiolitis obliterans
syndrome (BOS) grade. Bars
represent group mean and standard
deviation. p-values represent
unpaired t-tests. Median LCI for
BOS-2–3 was statistically higher



















FIGURE 3 Lung clearance index
(LCI) in patients with bronchiolitis
obliterans syndrome (BOS) on high-
resolution computed tomography
(HRCT), no BOS on HRCT and those
with no HRCT performed. Bars
represent group mean and standard
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better than those reported for LCI in other populations [10, 19, 20]. These are important initial steps in
establishing LCI as an outcome measure for post-transplant monitoring of OB.
ESTENNE et al. [11] have previously shown that single-breath wash-out tests became abnormal in post-lung
transplant monitoring an average of 18 months before changes were seen in spirometry. Technology and
understanding have progressed substantially since this initial work, and LCI has now become well
established in CF clinical and research practice [21]. LCI is very sensitive to early CF changes [19, 22],
progresses in the face of unchanged spirometry [23], responds better to interventions [24], and correlates
better with radiographic evidence of structural disease and air trapping than spirometry [25]. In contrast,
only a small number of MBW studies have been performed in populations with OB [13, 14, 26]. These
have all differed considerably in the technologies and tracer gases used to perform MBW, as well as the
populations being studied (including OB due to the effects of chronic rejection and inflammation in the
donor lungs post-transplant and due to graft versus host disease in bone marrow transplant recipients).
The cumulative evidence would therefore indicate that ventilation heterogeneity is an early feature of OB,
irrespective of its pathogenesis. These studies all lend support to the hypothesis that assessments of
ventilation heterogeneity are able to detect OB before it is sufficiently advanced or widespread to reduce
airflow at the mouth, as captured by spirometry. We have also shown here that LCI is scalable and that it
is elevated in those with pre-BOS, a putative early stage of OB that may be more reversible and amenable
to future therapeutic intervention. These findings are supported by a recent study on ventilation magnetic
resonance imaging (MRI) in paediatric stem-cell transplant patients, which showed evidence of ventilation
defects even in those with normal spirometry [27]
Since spirometry is used to diagnose BOS, we do not have an independent gold standard against which to
compare sensitivity of LCI and spirometry. However, only a single patient had a normal LCI but a low
FEV1, supporting the hypothesis that LCI is more sensitive than FEV1 to early OB. In addition, FEF25–75%,
which is believed to capture small airway mechanics more closely than FEV1, displayed better concordance
with LCI than did FEV1 (75% versus 47%). Without detailed history of the donor lungs, it is possible that
elevated LCI may in some cases reflect the pre-transplant history of the lungs rather than recent OB.
However, there is good separation based on LCI between patients with different grades of BOS, and also
between those with and without independent evidence of OB from HRCT.
Phase 3 slope analysis has been used in previous studies to separate gas mixing abnormalities into
components based on gas flow in the airways (Scond) and gas diffusion–convection interactions in the lung
periphery (ventilation heterogeneity of the acinar lung zone (Sacin)). In our study, LCI appeared to perform
best at separating the different BOS grades, followed by Scond and then Sacin. Scond, but not Sacin, separated
BOS-0 from the milder stages of BOS (BOS-0p and BOS-1). Conversely, THOMPSON et al. [28] showed an
increase in Sacin but not Scond across BOS stages using nitrogen washout, although in their study, the only
statistically significant differences were between Sacin in established BOS stages 1–3 versus 0, but not
BOS-0p. There are important differences between the two study methods however, in particular the choice
of tracer gas. Our data would suggest that it is only when disease in the conductive compartment reaches a
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FIGURE 4 a) Ventilation heterogeneity of the conductive lung zone (Scond) and b) ventilation heterogeneity of the acinar lung zone (Sacin) against
International Society for Heart and Lung Transplantation (ISHLT) bronchiolitis obliterans syndrome (BOS) grade. Bars represent group mean and
standard deviation. For details of the statistical differences between groups, see table 1.
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become evident from phase 3 slope analysis. Use of dynamic functional and structural imaging such as
ventilation MRI may help inform this debate in future.
One new observation from this study was the presence of very significant cardiogenic oscillations
superimposed on the gas wash-out traces in a proportion of wash-outs. These are a well-recognised
phenomenon in MBW, first described in 1954 and attributed to heart-synchronous fluctuations in gas
concentration, flow or pressure within the lungs [29]. There are no previous detailed reports of the
incidence or severity of cardiogenic oscillations, but these wash-out traces were analysed by an experienced
team and they are rarely encountered to the degree seen here, either in health or disease. The high
incidence of this phenomenon may be a consequence of lung transplant surgery, which involves opening
the pericardium and sewing the donor left atrial cuff onto the recipient left atrium. This will conceivably
alter cardiopulmonary haemodynamics and pave the way for more prominent cardiogenic oscillations [30].
The main limitation of this study is the cross-sectional design. Thus, although we are able to report on
LCI post-transplant, it is not possible to know how much of the abnormality seen is due to disease
progression. These are details that can only be explored in a longitudinal study. A strength of this study is
that we have used an exogenous tracer gas (SF6) to perform MBW, and a closed-circuit wash-in that has
allowed more rapid completion of the assessments than the conventional open-circuit method.
In summary, we have shown that MBW is feasible and reproducible in a population of ambulant, adult
DLTx or HLTx recipients. Our novel closed-circuit method and portable apparatus allow more rapid
testing and increase clinical applicability. These data also demonstrate the potential for increased
sensitivity of LCI in the early and more mild stages of BOS evolution.
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